Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Menactra in Japanese Adults
NCT02591290Phase 4Completed
- Sponsor
- Sanofi
- Start
- Oct 2015
- Primary completion
- Mar 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of meningococcal A conjugate vaccine in meningococcal meningitis, sponsored by Sanofi. Primary endpoint: Number of Participants With Meningococcal Serogroups A, C, Y, and W-135 Antibody Titers >=1:128. Started Oct 2015; status: completed.
02
Drugs
meningococcal A conjugate vaccine
03
Conditions
meningococcal meningitis
Beyond the preview
Go deeper on NCT02591290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02591290.